Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT04138927Enrolling by invitationPhase 3
Long-term fostamatinib use for warm autoimmune anemia
This study checks the benefits and safety of continuing fostamatinib over the long term for people with warm autoimmune hemolytic anemia. It may help by reducing the body’s immune attack on red blood cells, and it’s designed for people who already finished a prior part of the study.
Los Angeles, CaliforniaAges 18–100 - NCT07165769RecruitingPhase 2
ZGR combo for newly diagnosed spleen lymphoma with large cells
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people newly diagnosed with splenic B-cell lymphoma that has large cells (prominent nucleoli). The goal is to see if this drug combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06480552RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT02852213RecruitingPhase 1
Dose-check study for children with AADC deficiency using brain surgery
This Phase 1 trial tests how safe different treatment doses are for children with AADC deficiency, using MRI-guided brain surgery. It may help improve movement and developmental progress after standard medicines did not work well enough.
San Francisco, CaliforniaAges 2 years+ - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT07095465Enrolling by invitationPhase 3
Long-term study of ACP-204 for psychosis in Lewy body dementia
This study tests a medication called ACP-204 for psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a long-term extension open to patients who completed a previous ACP-204 study, to see if the drug continues to be helpful and safe.
Irvine, CaliforniaAges 55–84 - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07363967RecruitingPhase 1
Study of SWA1211 for advanced solid tumors
This trial tests a new oral drug, SWA1211, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06169579Enrolling by invitationPhase 1
Trial of ND-003 for advanced solid cancers
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Xiamen, FujianAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Homewood, AlabamaAges 55–90 - NCT07105254RecruitingPhase 2
Roflumilast foam study for children with vitiligo
This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.
Dallas, TexasAges 2–18 - NCT05749900RecruitingPhase 1/Phase 2
First-line antibody, chemo, and immunotherapy for HER2 bile duct cancer
This trial studies a combination of trastuzumab (an antibody), gemcitabine and cisplatin (chemo), plus nivolumab (immunotherapy) as the first treatment for advanced HER2-positive biliary tract cancer. It may help shrink tumors and improve outcomes by targeting HER2 and boosting the immune system.
SeoulAges 19 years+ - NCT06657859Enrolling by invitationPhase 2
Extended study of GLM101 for PMM2-CDG patients
This study is for people who already completed a previous trial of GLM101 for PMM2-CDG. It offers continued access to the treatment while doctors monitor safety and effects.
Minneapolis, MinnesotaAges 2 years+ - NCT06484868RecruitingPhase 4
Study of metreleptin for partial lipodystrophy
This trial tests an open-label study of metreleptin in people with partial lipodystrophy, a condition where fat is lost from some areas of the body. The goal is to see if the drug can help manage related health problems.
LilleAges 12 years+ - NCT05244486Recruiting
RestoreX traction therapy after prostate surgery
This trial studies whether RestoreX penile traction can help preserve erectile function after a prostatectomy (surgery to remove the prostate), especially when nerves are spared. If you qualify, you may be asked to use the device and be followed over time to see how erections change.
Orem, UtahAges 18 years+ - NCT07568730RecruitingPhase 2
Testing Lacripep eye drops for neurotrophic keratitis
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
Carmel, IndianaAges 18 years+ - NCT07089615Recruiting
Capsule vs colonoscopy for polyp detection
This trial tests a new capsule that you swallow to take pictures of your colon. It may help find polyps (growths that can turn into cancer) as well as a standard colonoscopy does.
Chula Vista, CaliforniaAges 45–75 - NCT07542808RecruitingPhase 2/Phase 3
Stem cell treatment vs. hyaluronic acid for knee arthritis
This study tests whether an injection of stem cells (special cells that can help repair tissue) works better than a standard hyaluronic acid injection for knee osteoarthritis pain. Both treatments are injected into the knee to reduce pain and improve function.
Abu DhabiAges 18 years+ - NCT06369259RecruitingPhase 2
Study of avutometinib, defactinib, and cetuximab for advanced colorectal cancer
This trial tests a combination of three drugs for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if combining these drugs can shrink tumors or slow cancer growth.
Houston, TexasAges 18 years+ - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
La Jolla, CaliforniaAges 18 years+ - NCT07563855Recruiting
Testing a Wellness Product for Digestive Health
This study tests whether a PepsiCo health and wellness product can improve digestive and overall health. You'll take the product daily for 4 weeks and provide blood and stool samples to help researchers understand how it affects your body.
Del Mar, CaliforniaAges 21–75
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.